Aktuellt
SENASTE
Redeye comments on Scandion Oncology presenting more details on CORIST part 3 results at its recent investor and R&D event. We understand Scandion targets running a randomised controlled phase IIb trial in mCRC, preceded by a smaller preparatory trial. We appreciate the company targeting trials that will reveal randomised controlled data, considering that comparisons to historical controls are indicative rather than conclusive. We adjust our estimates for the company’s updated clinical strategy.
LÄS MER
